Raymond James Financial
TARS icon

Raymond James Financial’s Tarsus Pharmaceuticals TARS Stock Holding History

Raymond James Financial’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.88M Sell
29,945
-4,839
-14% -$309K ﹤0.01% 3526
2026
Q1 		$2.44M Sell
34,784
-865
-2% -$60.4K ﹤0.01% 3192
2025
Q4 		$2.92M Sell
35,649
-13,690
-28% -$1.02M ﹤0.01% 2950
2025
Q3 		$2.93M Buy
49,339
+4,624
+10% +$228K ﹤0.01% 2880
2025
Q2 		$1.81M Buy
44,715
+24,348
+120% +$1.1M ﹤0.01% 3157
2025
Q1 		$1.05M Buy
20,367
+368
+2% +$18.2K ﹤0.01% 3456
2024
Q4 		$1.11M Buy
+19,999
New +$908K ﹤0.01% 3383

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Raymond James Financial's TARS Position: Q2 2026 in Review

Raymond James Financial reduced its Tarsus Pharmaceuticals (TARS) stake by 14% in Q2 2026, selling an estimated $309K and leaving 29,945 shares worth $1.88M. The position accounts for ﹤0.01% of the portfolio, ranked #3526.

Raymond James Financial first reported a position in TARS in Q4 2024 and has held it in 7 quarters since. The position peaked at $2.93M in Q3 2025. 256 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Raymond James Financial held 29,945 shares of Tarsus Pharmaceuticals worth $1.88M as of Q2 2026.
  • Raymond James Financial sold 4,839 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $309K.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #3526 holding.
  • Raymond James Financial first reported a position in Tarsus Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Raymond James Financial's Tarsus Pharmaceuticals position peaked at $2.93M in Q3 2025.
  • 256 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.